Cargando…

P705: AZACYTIDINE THERAPY REVERTS MDS-ASSOCIATED CHANGES IN MSC-DERIVED EXTRACELLULAR MATRIX

Detalles Bibliográficos
Autores principales:	Bains, Amanpreet, Schulz, Julia, Magno, Valentina, Radanovic, Toni, Rother, Sandra, Cross, Michael, Xiaofan, Xie, Werner, Carsten, Wobus, Manja, Platzbecker, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428782/ http://dx.doi.org/10.1097/01.HS9.0000969724.62560.97

Ejemplares similares

Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes
por: Bains, Amanpreet Kaur, et al.
Publicado: (2022)

Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells
por: Wobus, Manja, et al.
Publicado: (2021)

Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML
por: Dubois, Alix, et al.
Publicado: (2020)

Controversies on the Consequences of Iron Overload and Chelation in MDS
por: Vinchi, Francesca, et al.
Publicado: (2020)

Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation
por: Schönefeldt, C, et al.
Publicado: (2013)

Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?
por: Baer, Constance, et al.
Publicado: (2023)

Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
por: Weidner, Heike, et al.
Publicado: (2022)

Are We Ready For “Triplet” Therapy in Higher-Risk MDS?
por: Brunner, Andrew M., et al.
Publicado: (2023)

Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
por: Kubasch, Anne Sophie, et al.
Publicado: (2018)

An evaluation of the Hitachi 705 analyser
por: Ferré, C., et al.
Publicado: (1984)

Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)
por: Kotsianidis, Ioannis, et al.
Publicado: (2019)

Activation of distinct inflammatory pathways in subgroups of LR-MDS
por: Schneider, Marie, et al.
Publicado: (2023)

Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
por: Ørskov, Andreas D., et al.
Publicado: (2015)

Prognostic impact of peripheral blood Wilms’ tumour 1 mRNA expression levels in response to azacytidine in MDS: A single-centre analysis
por: Maeda, Tomoya, et al.
Publicado: (2020)

Significant improvement of bone marrow-derived MSC expansion from MDS patients by defined xeno-free medium
por: Altrock, Eva, et al.
Publicado: (2023)

Development of an Oral Form of Azacytidine: 2′3′5′Triacetyl-5-Azacytidine
por: Ziemba, Amy, et al.
Publicado: (2011)

Dalcetrapib: JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381
Publicado: (2012)

Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis
por: Yamada, Kentaro, et al.
Publicado: (2016)

Azacytidine Treatment for VEXAS Syndrome
por: Raaijmakers, Marc H. G. P., et al.
Publicado: (2021)

Averages of Weight and Chest Measurements of 705 Madras Coolies
por: Nicol, Burton
Publicado: (1911)

705 Evaluation of Invasive Fungal Infections in the Burn ICU
por: Pournezhad, Sam, et al.
Publicado: (2023)

Will It Revert to Pageantry and Burlesque?
Publicado: (1920)

Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway
por: Balaian, Ekaterina, et al.
Publicado: (2018)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes
por: Raj, Kavita, et al.
Publicado: (2006)

MDS subclassification—do we still have to count blasts?
por: Huber, Sandra, et al.
Publicado: (2023)

Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells
por: Imanishi, Satoshi, et al.
Publicado: (2017)

Turbidimetric analysis on the Hitachi 705 using orosomucoid as a model
por: Legg, E. F., et al.
Publicado: (1984)

705 Correlation of Radiologic Tests in the Diagnosis of Brucellosis with Osteoarticular Involvement
por: Kurtaran, Behice, et al.
Publicado: (2014)

Improving properties of the nucleobase analogs T-705/T-1105 as potential antiviral
por: Jia, Xiao, et al.
Publicado: (2021)

705. Community Acquired Gastrointestinal Infections among Transplant Recipients
por: Al-Obaidi, Mohanad, et al.
Publicado: (2021)

Tyrosine 705 Phosphorylation of STAT3 Is Associated with Phenotype Severity in TGFβ1 Transgenic Mice
por: Guadagnin, Eleonora, et al.
Publicado: (2015)

Revertant Mosaicism in Epidermolysis Bullosa
por: Meyer-Mueller, Cameron, et al.
Publicado: (2022)

A "late-but-fitter revertant cell" explains the high frequency of revertant mosaicism in epidermolysis bullosa
por: van den Akker, Peter C., et al.
Publicado: (2018)

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
por: FURUTA, Yousuke, et al.
Publicado: (2017)

The prevalence and risk factors of prostatic calcification: an analysis of 68 705 subjects
por: Tang, Zhuang, et al.
Publicado: (2018)

Favipiravir (T-705) protects against Nipah virus infection in the hamster model
por: Dawes, Brian E., et al.
Publicado: (2018)

The role of p-Stat3 Y705 immunohistochemistry in glioblastoma prognosis
por: Susman, Sergiu, et al.
Publicado: (2019)

Anti-influenza Virus Activity of Methylthio-Formycin Distinct From That of T-705
por: Takizawa, Naoki, et al.
Publicado: (2022)

Evaluation of Antiviral Efficacy of Ribavirin, Arbidol, and T-705 (Favipiravir) in a Mouse Model for Crimean-Congo Hemorrhagic Fever
por: Oestereich, Lisa, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cp43uloig4meohomja51alar5d